17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A randomized controlled trial of intranasal ketamine in major depressive disorder.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The N-methyl-D-aspartate glutamate receptor antagonist ketamine, delivered via an intravenous route, has shown rapid antidepressant effects in patients with treatment-resistant depression. The current study was designed to test the safety, tolerability, and efficacy of intranasal ketamine in patients with depression who had failed at least one prior antidepressant trial.

          Related collections

          Author and article information

          Journal
          Biol. Psychiatry
          Biological psychiatry
          1873-2402
          0006-3223
          Dec 15 2014
          : 76
          : 12
          Affiliations
          [1 ] Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York.
          [2 ] Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
          [3 ] Department of Anesthesiology, Icahn School of Medicine at Mount Sinai, New York.
          [4 ] Department of Health Evidence and Policy, Icahn School of Medicine at Mount Sinai, New York.
          [5 ] Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York; James J. Peters Veterans Affairs Medical Center, Bronx, New York.
          [6 ] Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York.
          [7 ] Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York; Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York.
          [8 ] Mood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York; Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York. Electronic address: james.murrough@mssm.edu.
          Article
          S0006-3223(14)00227-3 NIHMS582382
          10.1016/j.biopsych.2014.03.026
          24821196
          e9a7be4b-97ed-48c4-9a33-407b992222ff
          Copyright © 2014 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
          History

          Antidepressant,depression,glutamate,intranasal,ketamine,treatment resistant

          Comments

          Comment on this article